Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEN1309 in CD205+ Solid Tumors and NHL
NCT03403725Phase 1Terminated
- Sponsor
- Menarini Group
- Start
- Aug 2017
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of OBT076 in solid tumor and non-Hodgkin lymphoma (NHL), sponsored by Menarini Group. Primary endpoints: Maximum-Tolerated Dose at 21 days and Dose-Limiting Toxicity at 21 days. Started Aug 2017; status: terminated.
02
Drugs
OBT076
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03403725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403725.